Scissors Bandage Utility
Defense Logistics Agency, DLA Acquisition Locations | Published November 4, 2011 - Deadline November 28, 2011
The Defense Medical Materiel Program Office (DMMPO announces a Request for Incentive Agreement Quotation (RFIAQ) for the standardization of Scissors Bandage Utility. The Medical Material Enterprise Standardization Office (MMESO) North is the lead MMESO for this project.
The primary objective of this effort is to standardize the quality of care across the Military Treatment Facilities (MTFs) and operational assemblages based on the critical balance of clinical efficacy and value. The intent for this initiative is the standardization of a clinically preferred product (s) and source for institutional and operational medicine requirements at the lowest price. It is intended for this initiative to result in the reduction of Stock Keeping Units (SKUs) and National Stock Numbers (NSN). Standardized products must be obtained through the Department of Defense (DoD) Prime Vendor (PV) Program. As an enterprise-wide clinically driven program, vendors and products must meet specific technical requirements plus products must meet or exceed specific clinical performance expectations as a primary consideration. Among vendors who meet the technical requirements and the products that meet or exceed the clinical acceptability, then clinically preferred, best value will determine selection. It is intended that the selected standardized vendor (s) for this Standardization Action (SA) support the enterprise goal of medical materiel standardization that combines operational and institutional requirements. The government is seeking a single award for this SA.
The major facilities in the MMESOs North, South, West, Pacific and Europe (hereafter referred to as MMESOs) include but are not limited to MMESO North: Walter Reed National Military Medical Center, Portsmouth Naval Hospital, Womack Army Medical Center, Wright-Patterson Medical Center; MMESO South: Wilford Hall Ambulatory Surgical Center, Brooke Army Medical Center, Eisenhower Army Medical Center, Darnall Army Medical Center, Keesler Medical Center, Naval Hospital Jacksonville, Martin Army Community Hospital, Ft. Benning, GA; MMESO West: Madigan Army Medical Center, William Beaumont Army Medical Center, Naval Medical Center San Diego, Irwin Army Community Hospital, Mike O'Callaghan Federal Hospital; MMESO Pacific: Tripler Army Medical Center, 18th Medical Group, Kadena AB, Okinawa, US Naval Hospital, Yokosuka, Japan; MMESO Europe: Landstuhl Regional Medical Center, Landstuhl, GE, US Naval Hospital, Naples, Italy, the 48th Medical Group, Lakenheath, UK; and Operational U.S. Forces.
This SA is part of the Medical/Surgical Prime Vendor (PV) program executed by the Defense Logistics Agency (DLA) Troop Support, Directorate of Medical Materiel. To participate in this SA, your company must have a Distribution and Pricing Agreement (DAPA) and a separate commercial agreement with the current Med-Surg PV for each MMESO region, i.e., Cardinal Health, and Owens & Minor. This requirement is pursuant to the DAPA clause by which DAPA holders agree to the standardization initiative and agree to allow PVs to distribute their products. The Incentive Agreement (IA) resulting from this RFIAQ is a supplement to the PV Program and is not a contract. For additional information regarding DLA TS Medical's PV program please access its web site at https://dmmonline.dscp.dla.mil.
This IA standardization initiative will be a Three Phase IPP Process: vendor(s) who meets the technical / company requirements in Phase I will be invited to participate in Phase II where no-charge products will be provided for clinical evaluation and Phase III where pricing will be required for submittal. Phase II and Phase III will be run concurrently. The resulting IA will be for a base period of two (2) years (24 months) from date of selection with three (3) 12-month "option" periods not to exceed a total of 5 years. Anticipated selection date is February 2012. The selection will be based on the product and vendor that provides the Best Value to the enterprise. Products and vendors that meet or exceed the technical and clinical performance requirements will be considered clinically preferred products and sources. Among vendors who meet the technical requirements and the products that meet or exceed the clinically preferred standard, best price (i.e. lowest Aggregate Post Standardization Cost) will determine selection.
Points of Contact: Ms. Toni Massenburg, MMESO North, Team Leader, firstname.lastname@example.org and 571-231-5451 and Ms. Gail Tucker-Carlisle, MMESO North, Clinical Analyst, email@example.com.
B. Products & Performance Required
The MMESOs are seeking product line items in the category of Scissors, Bandage Utility. Within the MMESOs, this product line has an estimated annual dollar requirement of $233,290.66. This forecast is based on historical usage during a recent 12-month period. Based on usage data, twenty-one (21) of the total forty six (46) line items, account for 75.8% ($176,884.43) of the total volume in sales ($233,290.66) in the MMESOs and are clinically significant. The top high volume usage lines for this project are shown in the Technical/Company Requirements below.
C. Instructions to Vendors
Vendors interested in participating in this standardization initiative will provide an initial response to the FBO-posted RFIAQ to Ms. Toni Massenburg, Team Leader, firstname.lastname@example.org and Gail Tucker-Carlisle, RN, Clinical Analyst, email@example.com. The vendor's initial responses will include detailed information requested in the technical/company requirements listed in the FBO RFIAQ and must also include: (1) Company name and address; (2) Company Point of Contact (POC) (Name and Phone Number, Fax Number, and E-mail address); and (3) Identification of the RFIAQ to which the vendor is responding. Due to the potential for e-mail to be lost in transmission, from network security, etc., vendor is strongly encouraged to confirm with the MMESO North that its initial submission, quote and literature actually arrived at the MMESO North via e-mail. Each submitting vendor is advised to confirm receipt, allowing adequate time for resubmission before the due date/time, should a problem occur with the first submission. Vendor should complete and submit the attached document. A vendor, who cannot open the attachments, may contact the POC as noted in the FBO RFIAQ and a copy will be provided via an alternate method (fax, e-mail or hard copy). Vendors that do not meet the deadline of COB 5:00PM Eastern Standard Time (EST) on the date listed for closing will be disqualified from further consideration in the standardization initiative.
D. Source Selection Procedures
The MMESO Joint Product Review Board (JPRB) will serve as the forum for clinical recommendations for product selection, seeking and evaluating opportunities for committed volume purchase agreements, and coordinating logistics efforts in support of DoD Components. The boards are chaired by Designated Senior Logisticians (DSLs) and co-chaired by Designated Senior Clinicians (DSCs) in the MMESO AORs and include clinicians and logisticians for MTFs within each MMESO. The Clinical Advisory Committee (CAC) members are the deciding officials for this initiative. Vendor quotes should contain the vendor's best discounts off of the vendor's DAPA pricing based on committed volume of 80% of the total requirements of the MTFs in the MMESOs. The MMESO North reserves the right to conduct discussions and request revised quotes, if determined necessary.
Phase I Technical / Company Requirements
The MMESO CPT will review the responses from the vendors and determine which vendors meet the technical/company requirements. Vendors must meet the technical requirements for continued consideration in this initiative. Failure to provide any requested information or meet any of the technical requirements will be disqualify the vendor from further consideration. A vendor who meets the following technical/company requirements will be qualified and invited to participate in the clinical/performance selection and will be requested to submit products for testing and their best price discount quotes via an email communication. All communications of significant acquisition milestones (such as invitations to participate, or notices of disqualification) should be digitally signed.
During the pre-source selection procedures, CPT approved the technical/company requirements outlined below. The thirteen (13) requirements below must be answered with the vendor's initial submittal and required documents by the response date stated in the FBO announcement: A vendor who does not meet these requirements or who does not submit documentation to support these requirements with initial submittal will be disqualified in Phase I.
1. At a minimum the vendor must provide the following: Scissors Bandage Utility product line which
includes at least two sizes; straight, blunt, curved and angular tipped; and smooth and serrated blades.
7" Bandage Utility Scissor
7 ½" Bandage Utility Scissor
*Operational usage items are included in this list of Scissors, Bandage Utility.
b. Vendor must provide a complete itemized list of products supplied (manufactured and/or distributed by
brands) via Microsoft Excel spread sheet, and a product catalog and literature in response to this
RFIAQ. Vendors are required to supply all items in all sizes and device types.
2. Vendor must provide Scissors, Bandage Utility that are made from stainless steel for long-lasting durability with a Rockwell hardness of HRC 46 to 50.
3. Vendors must provide supporting documentation that all products meet the industry production and safety standards used in manufacturing Scissors, Bandage Utility products. Vendor must provide documentation or a statement revealing the alloy content of all, especially products that are clearly labeled nickel-free, wear, corrosion/rust and shock resistant metal that meet AAMI/ASTM standards regarding mechanical properties and hardness.
4. Vendor must provide Scissors, Bandage Utility that can safely cut plastic, light metal, bandages and multiple layers of dressings with ease, have razor sharp blades that help reduce hand fatigue, have ring handles that are ambidextrous, and have a large finger ring that helps relieve pressure on the third metacarpal.
5. Vendor must provide Scissors, Bandage Utility that are fully autoclavable to 143 degrees centigrade or 290 degrees Fahrenheit and sterilizable by EtO or gamma radiation.
6. Vendor must provide Scissors, Bandage Utility that are sterile and individually packaged.
7. Vendor must provide Scissors, Bandage Utility that has fluoride-coated blades that help prevent adhesive or fiberglass casting material from sticking to blade surfaces.
8. Vendor must provide Scissors, Bandage Utility that has a design that incorporates one serrated blade on one and a razor bevel honed edge with round-ended blades and a knob at the point for slipping under or lifting the bandage away from the skin to prevent injury.
9. Vendor must have an identified customer service representative available for on-site assessment, on-site instructional sessions (in-services), and on-going clinical support as required at no cost to the government for the Scissors, Bandage Utility product line.
10. Vendors must have a Distribution and Pricing Agreement (DAPA) number for the Scissors, Bandage Utility. Vendor must provide DAPA number or provide documentation the DAPA number has been applied for.
11. Vendor must have agreements with the current Med/Surg Prime Vendors for each MMESO AOR, i.e. Cardinal Health and Owens & Minor for Scissors, Bandage Utility, or be in the process of obtaining Prime Vendor agreements.
12. Vendors will be required to submit discounts off of DAPA for all products included in this standardization initiative when pricing is requested in Phase III. Where lower FSS prices are available, DAPA holders are required by previous agreement to provide the FSS price as the DAPA price. A vendor shall not quote FSS prices as the discounted price for purposes of this standardization initiative. A vendor who does not provide discounts off DAPA in Phase III for all products will be disqualified.
13. Vendor must indicate country from which each line item is an end product, IAW Trade Agreements Act. Vendors having existing DAPA numbers must also ensure that all DAPA line items/end products in the subject product line list the proper Trade Agreements Act country in the DAPA Management System.
Phase II Clinical Performance Evaluation:
Following acceptability of the technical/company requirements, the MMESO North, on behalf of the CPT, will request product sample sets from the product group to be sent to the specific CPT members at the participating MTFs. Vendor will be given 30 calendar days from the issue of the notice in which to deliver the product samples for clinical evaluation at Phase II. Product samples must be shipped to arrive at the designated addresses by 5:00PM local time for each MTF on the 30th calendar day after the notice to ship. Vendor must be able to deliver product literature, training materials and evaluation samples as requested MMESO Pacific via FedEx or UPS AND to the MMESO Europe via United States Postal Service (USPS) Express Mail AND throughout the United States by selected shipping method when requested in Phase II. Vendor must send the MMESO North verification regarding the shipment of literature and samples. This information will include the date of shipment, final delivery date, tracking numbers and the carrier used by the vendor. Vendor will provide only the following no cost product samples for clinical/performance evaluation. Unused samples will not be returned. Two (2) pairs of Scissors Bandage Utility listed below are to be provided as samples to each of the evaluation sites as identified in the letters of invitation.
Items to be sent
7½" Bandage Utility Scissor
Each evaluator will evaluate each Scissors Bandage Utility product sample from each vendor against the established requirements. A trial will consist of evaluating sample products from a single vendor, evaluated against the requirements and recorded on a single evaluation form per vendor. Each evaluator will evaluate or trial each participating vendor's product line. The clinical/performance acceptability evaluation will last for fourteen (14) calendar days. The acceptability evaluation will be conducted using the below listed requirements with responses as either a "YES" (meets/passes requirements) or "NO" (does not/fails to meet requirements) answers. The MMESO JPRB has established that the Clinically Preferred threshold of products for standardization will be eighty percent (80%) of the requirements questions answered as "YES" (meets/passes requirements).
A vendor scoring below the clinically preferred threshold will be disqualified from selection for this standardization initiative. A vendor who has been disqualified will be notified in writing upon disqualification.
Of those Vendors who are qualified as clinically preferred, selection will be based on best price. Clinical/performance acceptability evaluations by the participating CPT facilities will be tabulated resulting in one score per participating MMESO per vendor. The participating MMESOs' scores by vendor will then be combined resulting in one final vendor performance evaluation score. All clinical/performance acceptability evaluations will tabulated by the MMESO North and results will be forwarded to the MMESO CPT for final review.
There will be approximately thirteen (13) MTFs enterprise wide that will be evaluating products.
During the acquisition planning process, the MMESO CPT validated/approved the clinical/performance requirements outlined below.
1. (Infection Control (NPSG).07.05.01and ASTM F1089-10 and ISO 13485:2003/9001 -The products is non-staining and non-corrosive). The Scissors can be disinfected, using the appropriate sterilization methodology
for scissors, without evidence of rust, discoloration, or blunting of the blades.
2. (Clinician Efficiency of Care/Patient and Staff Safety and ASTM F899) The surfaces of the instrument areuniformly finished and free of burrs, especially at the tip of cutting edge; cracks, and coarse marks.
3. (Clinician Efficiency of Care/Patient and Staff Safety, FDA (21CFR820) and ISO 13485). The jaw tips fold and lock together when the first ratchet position is engaged with no visible misalignment of the jaws. The screw/hinge lock is secure and engages in a smooth and progressive manner.
4. (Clinician Efficiency of Care, ISO13485:2003 and ISO 9001). The inside surfaces of the finger rings are well rounded and polished, ambidextrous, and ergonomically contoured for user's comfort.
5. (Infection Control (NPSG).07.05.01). The scissors are fluoride coated so that fibers or adhesives from dressing tapes do not stick to the blades.
6. (Clinician Efficiency of Care/ Patient Safety) Scissors are designed to have razor sharp blades to cut bandages and multiple layers of dressings cleanly and easily while having a blunt end to prevent injury.
Phase III Pricing Analysis:
Upon completion of the Phase I - Technical/Company Requirements, a vendor who is found technically acceptable will be qualified/invited to provide product samples and price discount quotes concurrently. A vendor will be given 30 calendar days from the date of pricing requests, to submit IA pricing quotes, in a prescribed electronic spreadsheet format, based upon the requirements of the MMESOs. Pricing will be submitted to MMESO North by 5:00 PM EST thirty (30) calendar days after the issue date of the vendor notice to submit best price quotes. Vendor quotes should contain the vendor's best product matches for the specific products requested in this announcement. Vendor quotes should contain the vendor's best discounts off of the vendor's DAPA pricing for the products identified in this announcement based on committed volume of 80% of the total requirements of the MTFs in the MMESOs. Price will be analyzed based on the projected Aggregate Post-Standardization costs for each vendor. Aggregate Post-Standardization Cost will be calculated for each vendor by applying the vendors' offered prices to the anticipated annual usage of the enterprise. Unmatched items will be represented in the Post-Standardization Cost at a baseline non-discounted price (current DAPA price of product with highest procurement). Among the products and sources that were determined to be clinically preferred, the best price Aggregate Post-Standardization Cost will be selected for each MMESO AOR.